NO2948441T3 - - Google Patents

Info

Publication number
NO2948441T3
NO2948441T3 NO14743689A NO14743689A NO2948441T3 NO 2948441 T3 NO2948441 T3 NO 2948441T3 NO 14743689 A NO14743689 A NO 14743689A NO 14743689 A NO14743689 A NO 14743689A NO 2948441 T3 NO2948441 T3 NO 2948441T3
Authority
NO
Norway
Application number
NO14743689A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2948441T3 publication Critical patent/NO2948441T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO14743689A 2013-01-28 2014-01-27 NO2948441T3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020130009282A KR20140096571A (ko) 2013-01-28 2013-01-28 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
PCT/KR2014/000752 WO2014116070A1 (en) 2013-01-28 2014-01-27 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one

Publications (1)

Publication Number Publication Date
NO2948441T3 true NO2948441T3 (ru) 2018-05-26

Family

ID=51227806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14743689A NO2948441T3 (ru) 2013-01-28 2014-01-27

Country Status (17)

Country Link
US (1) US9518043B2 (ru)
EP (1) EP2948441B1 (ru)
JP (4) JP6461011B2 (ru)
KR (1) KR20140096571A (ru)
CN (1) CN104981467B (ru)
AU (1) AU2014210494B2 (ru)
BR (1) BR112015017597B1 (ru)
CA (2) CA2898433C (ru)
DK (1) DK2948441T3 (ru)
ES (1) ES2662863T3 (ru)
IL (2) IL240197B (ru)
MX (1) MX362763B (ru)
NO (1) NO2948441T3 (ru)
PH (2) PH12015501636B1 (ru)
RU (2) RU2018137882A (ru)
WO (1) WO2014116070A1 (ru)
ZA (1) ZA201506241B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
MX2018001350A (es) * 2015-08-11 2018-05-22 Principia Biopharma Inc Procesos para preparar un inhibidor de fgfr.
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
WO2022043923A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative
CN117567466B (zh) * 2024-01-16 2024-04-16 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02275891A (ja) 1988-12-29 1990-11-09 Tsumura & Co 新規な複核白金錯体および該錯体を有効成分とする抗腫瘍剤
HU227759B1 (en) 1994-08-23 2012-02-28 Smithkline Beecham Plc Improved pharmaceutical formulations containing ibuprofen and codeine
KR980008219A (ko) 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP3687025B2 (ja) 1998-06-04 2005-08-24 東和薬品株式会社 安定なマレイン酸エナラプリル錠剤
KR20020032612A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 유도체 및 그의 의약으로서의 용도
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
MXPA04009536A (es) 2002-03-30 2005-01-25 Boehringer Ingelheim Pharma Compuestos heterociclos biciclicos, composiciones farmaceuticas que contienen estos compuestos, su utilizacion y procesos para su preparacion.
UA83252C2 (ru) * 2003-09-19 2008-06-25 Астразенека Аб Производные хиназолина, способ их получения (варианты), фармацевтическая композиция на их основе, промежуточное соединение
EP1670782B1 (en) 2003-09-19 2007-02-14 AstraZeneca AB Quinazoline derivatives
JP2007506716A (ja) 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ キナゾリン誘導体
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
DE10345875A1 (de) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
CN1934100A (zh) 2004-03-23 2007-03-21 万有制药株式会社 取代喹唑啉或吡啶并嘧啶衍生物
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
ATE521603T1 (de) * 2005-02-26 2011-09-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
WO2007023073A2 (de) 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2007068552A1 (de) 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DK1847258T4 (da) 2006-04-13 2013-04-15 Acino Pharma Ag Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thieno[3,2-c]pyridin-derivater
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EA200901041A1 (ru) * 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR20100033379A (ko) 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
JP2012509321A (ja) * 2008-11-21 2012-04-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド 癌および他の疾患または障害の処置のための、4−[6−メトキシ−7−(3−ピペリジン−1−イル−プロポキシ)キナゾリン−4−イル]ピペラジン−1−カルボン酸(4−イソプロポキシフェニル)−アミドの乳酸塩およびその薬学的組成物
MY144136A (en) 2009-04-20 2011-08-10 Univ Sains Malaysia Throttle and brake lock
CA2787225A1 (en) 2010-01-12 2011-07-21 Nestec S.A. Methods for predicting response of triple-negative breast cancer to therapy
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법

Also Published As

Publication number Publication date
AU2014210494B2 (en) 2017-09-14
JP6784743B2 (ja) 2020-11-11
PH12019501676A1 (en) 2021-02-22
IL267303A (en) 2019-08-29
JP7051929B2 (ja) 2022-04-11
US9518043B2 (en) 2016-12-13
IL267303B (en) 2021-01-31
JP6461011B2 (ja) 2019-01-30
MX362763B (es) 2019-02-06
RU2671843C2 (ru) 2018-11-07
PH12015501636A1 (en) 2015-10-19
RU2015129994A (ru) 2017-03-10
DK2948441T3 (en) 2018-03-26
IL240197B (en) 2019-06-30
JP7377307B2 (ja) 2023-11-09
CA2898433A1 (en) 2014-07-31
JP2020125306A (ja) 2020-08-20
EP2948441A1 (en) 2015-12-02
PH12015501636B1 (en) 2015-10-19
CN104981467B (zh) 2017-10-24
CA3129936A1 (en) 2014-07-31
EP2948441A4 (en) 2016-07-06
BR112015017597A2 (ru) 2017-08-15
CN104981467A (zh) 2015-10-14
IL240197A0 (en) 2015-09-24
ZA201506241B (en) 2017-06-28
AU2014210494A1 (en) 2015-08-06
JP2019065034A (ja) 2019-04-25
BR112015017597B1 (pt) 2022-11-16
WO2014116070A1 (en) 2014-07-31
RU2018137882A (ru) 2019-03-21
MX2015009232A (es) 2016-04-28
JP2016505068A (ja) 2016-02-18
JP2022088570A (ja) 2022-06-14
KR20140096571A (ko) 2014-08-06
EP2948441B1 (en) 2017-12-27
CA2898433C (en) 2021-11-02
ES2662863T3 (es) 2018-04-10
US20150344458A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
AP2016009275A0 (ru)
BR102016010778A2 (ru)
BR112015007533A2 (ru)
BR112014019326A2 (ru)
BR112016011691A2 (ru)
BR112014020341A2 (ru)
BR112016012144A2 (ru)
BR112016011140A2 (ru)
BR112014017669A2 (ru)
BR112014021878A2 (ru)
BR112016003966A2 (ru)
BR112016008328A2 (ru)
BR112016001303A2 (ru)
BR112014019204A2 (ru)
BR112014017722A2 (ru)
BR112015015948A2 (ru)
BR112015027665A2 (ru)
BR112014017653A2 (ru)
BR112016008877A2 (ru)
BR112016000862A2 (ru)
BR112014017601A2 (ru)
BR112015015312A2 (ru)
BR112014024039A2 (ru)
BR112016009785A2 (ru)
NO2948441T3 (ru)